Objective of the clinical study

The first clinical study on the EYEOP1 device

This single centre pilot study has been carried out on a limited number of patients suffering from refractory glaucoma.
 
The first patients are being treated at the Edouard Herriot Hospital, Lyon (France), Department of Ophthalmology, Wing C.

Objectives

The study has many objectives.  These include confirming the tolerability and efficacy of the new UC³ therapeutic method.
 
An additional objective is to confirm the treatment dose.

Safety

This study has been approved by the French Health Products Safety Agency (AFSSAPS). AFSSAPS, which in particular makes judgements on the safety of the first patients treated, approved the study in light of the preclinical test results which were obtained from preliminary studies that lasted approximately 2 years and were conducted in collaboration with INSERM.

Discover the EYEOP1 system intended for HIFU treatment of refractory glaucoma